Lmcg Investments LLC Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)

Lmcg Investments LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,063 shares of the company’s stock after selling 173 shares during the quarter. Lmcg Investments LLC’s holdings in Eli Lilly and Company were worth $8,311,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company during the 4th quarter valued at $43,000. FPC Investment Advisory Inc. lifted its holdings in shares of Eli Lilly and Company by 358.3% in the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock worth $45,000 after buying an additional 43 shares during the period. Prudent Man Investment Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth $48,000. Compass Financial Services Inc purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth $50,000. Finally, Capital A Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter worth $63,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

LLY has been the subject of several research reports. Hsbc Global Res cut Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, May 30th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price target for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,011.37.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $766.78 on Thursday. The company has a market capitalization of $726.71 billion, a P/E ratio of 65.48, a P/E/G ratio of 1.40 and a beta of 0.48. The business’s 50 day moving average is $772.75 and its two-hundred day moving average is $799.41. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.58 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.78%. Eli Lilly and Company’s dividend payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.